Substituted Imidazo-Based Compounds as Ligand Directed Degraders of IRAK3

A compound of Formula (I):

• or a pharmaceutically acceptable salt thereof, wherein:
• A is C1-C6 alkyl, phenyl, C3-C6 cycloalkyl, 5- to 6-membered heteroaryl, or 6- to 10-membered heterocyclyl, wherein the phenyl, cycloalkyl, heteroaryl, and heterocyclyl are substituted by x R1 groups, and wherein the heteroaryl and heterocyclyl contain 1-3 heteroatoms selected from N and O;
• each R1 is independently halo, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkoxy, C1-C6 haloalkyl, or —SO2(C1-C6 alkyl);
• or two R1 groups on adjacent carbon atoms are taken together to form a fused C3-C6 cycloalkyl or a fused
• group;
• Ra and Rb are each H or are taken together to form an oxo group;
• Rc is H or C1-C6 alkyl;
• x is 0-5;
• R2 is H or C1-C6 alkyl;
• R3 is H or C1-C6 alkyl;
• R4 is H or C1-C6 alkyl;
• X1 is CH or N;
• X2 is N or CH2;
• Ring B is C3-C6 cycloalkylene or 5- to 7-membered heterocyclylene containing 1 or 2 nitrogen atoms;
• each R5 is independently halo, C1-C6 alkyl, or C1-C6 haloalkyl;
• w is 0-5;
• L1 is —C(O)(CH2)n—, —(CH2)n—, or —(CH2)nC(O)—;
• n is 1-6;
• Ring C is 5- to 10-membered heterocyclylene containing 1 or 2 nitrogen atoms;
• each R6 is independently halo, C1-C6 haloalkyl, or C1-C6 alkyl;
• y is 0-5;
• Ring D is
• R7a and R7b are each H or are taken together to form an oxo group;
• each R8 is independently halo, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 alkoxy;
• z is 0-4;
• X3 is N or CR9;
• R9 is H or C1-C6 alkyl;
• R10 is H or C1-C6 alkyl;
• each R11 is independently halo, C1-C6 alkyl, or C1-C6 haloalkyl;
• v is 0-4;
• and
• each is independently a single bond or double bond.